NYSE:HRC - Hill-Rom Stock Price, Forecast & News

$113.62

-1.52 (-1.32 %)

(As of 01/23/2020 04:00 PM ET)

Add

Compare

Today's Range

$113.15

Now: $113.62▼

$115.62

50-Day Range

$106.63

MA: $112.64▼

$116.37

52-Week Range

$93.88

Now: $113.62▼

$117.10

Volume755,200 shs

Average Volume397,156 shs

Market Capitalization$7.61 billion

P/E Ratio50.50

Dividend Yield0.74%

Beta0.83

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment. Read More…

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNYSE:HRC

Previous SymbolNYSE:HB

CUSIP43147510

CIK47518

Webhttp://www.hill-rom.com/

Phone312-819-7200

Debt

Debt-to-Equity Ratio1.13

Current Ratio1.31

Quick Ratio1.10

Price-To-Earnings

Trailing P/E Ratio50.50

Forward P/E Ratio20.55

P/E Growth1.78

Sales & Book Value

Annual Sales$2.91 billion

Price / Sales2.62

Cash Flow$8.06 per share

Price / Cash Flow14.10

Book Value$23.55 per share

Price / Book4.82

Profitability

EPS (Most Recent Fiscal Year)$5.08

Net Income$152.20 million

Net Margins5.24%

Return on Equity21.67%

Return on Assets7.55%

Miscellaneous

Employees10,000

Outstanding Shares66,956,000

Market Cap$7.61 billion

Next Earnings Date1/24/2020 (Confirmed)

OptionableOptionable

Receive HRC News and Ratings via Email

Sign-up to receive the latest news and ratings for HRC and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

Hill-Rom (NYSE:HRC) Frequently Asked Questions

What is Hill-Rom's stock symbol?

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?

Hill-Rom announced a quarterly dividend on Friday, November 8th. Shareholders of record on Monday, December 16th will be paid a dividend of $0.21 per share on Tuesday, December 31st. This represents a $0.84 annualized dividend and a yield of 0.74%. The ex-dividend date of this dividend is Friday, December 13th. View Hill-Rom's Dividend History.

How were Hill-Rom's earnings last quarter?

Hill-Rom Holdings, Inc. (NYSE:HRC) posted its earnings results on Friday, November, 1st. The medical technology company reported $1.69 earnings per share for the quarter, topping analysts' consensus estimates of $1.65 by $0.04. The medical technology company had revenue of $782.80 million for the quarter, compared to analysts' expectations of $759.14 million. Hill-Rom had a return on equity of 21.67% and a net margin of 5.24%. The firm's quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm posted $1.63 EPS. View Hill-Rom's Earnings History.

When is Hill-Rom's next earnings date?

Hill-Rom is scheduled to release their next quarterly earnings announcement on Friday, January 24th 2020. View Earnings Estimates for Hill-Rom.

How can I listen to Hill-Rom's earnings call?

Hill-Rom will be holding an earnings conference call on Friday, January 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Hill-Rom issued on next quarter's earnings?

Hill-Rom updated its FY20 earnings guidance on Friday, November, 1st. The company provided earnings per share guidance of $5.46-5.56 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.47. The company issued revenue guidance of +1-2% to $2.94-2.97 billion, compared to the consensus revenue estimate of $2.92 billion.

What price target have analysts set for HRC?

3 Wall Street analysts have issued 12 month price targets for Hill-Rom's stock. Their forecasts range from $116.00 to $138.00. On average, they anticipate Hill-Rom's share price to reach $126.00 in the next year. This suggests a possible upside of 10.9% from the stock's current price. View Analyst Price Targets for Hill-Rom.

What is the consensus analysts' recommendation for Hill-Rom?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.

What are Wall Street analysts saying about Hill-Rom stock?

Here are some recent quotes from research analysts about Hill-Rom stock:

1. According to Zacks Investment Research, "Hill-Rom exited the second quarter of fiscal 2019 on a strong note with better-than-expected numbers. The company saw a solid year-over-year increase in domestic revenues, driven by sturdy performance in Patient Support Systems and Front Line Care. We are upbeat to note the company’s strong momentum across its diversified product portfolio which includes Centrella Smart+ bed, Welch AllynConnex Spot Monitor, Monarch Airway Clearance System, Integrated Table Motion for the da Vinci Xi Surgical System. The acquisition of Voalte buoys optimism as it boosts Hill-Rom’s digital and mobile communications platform. Overall, Hill-Rom has outperformed its industry in the past six months. However, foreign exchange and a tough competitive landscape remain headwinds. Also, Hill-Rom’s global revenue growth was sluggish in the quarter." (6/6/2019)
2. Needham & Company LLC analysts commented, "HRC announced that it has entered into a definitive agreement to acquire Voalte (private) for $180M up front and up to $15M in commercial-based milestones. HRC believes it can absorb the dilutive impact of the deal in FY19, expects the transaction to close in F3Q19, and estimates the deal to become increasingly accretive beginning in FY20. Voalte offers smartphone and web-based applications that enable caregivers to communicate securely and provides managers data analytics tools, respectively. The Voalte deal seems to make financial (accretive to revenue growth and margins) and strategic (further diversifies HRC away from capital equipment sales and allows for cross-selling opportunities in its care communications business) sense, in our view, and we reiterate our Buy rating." (3/11/2019)

Has Hill-Rom been receiving favorable news coverage?

Media stories about HRC stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hill-Rom earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave press coverage about the medical technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Hill-Rom.

Are investors shorting Hill-Rom?

Hill-Rom saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,620,000 shares, a drop of 12.4% from the December 15th total of 1,850,000 shares. Based on an average daily volume of 404,400 shares, the short-interest ratio is currently 4.0 days. Currently, 2.4% of the shares of the company are short sold. View Hill-Rom's Current Options Chain.

Who are some of Hill-Rom's key competitors?

Some companies that are related to Hill-Rom include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

What other stocks do shareholders of Hill-Rom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), Paypal (PYPL), AK Steel (AKS), Endologix (ELGX), Walt Disney (DIS), Chipotle Mexican Grill (CMG), Micron Technology (MU), Mastercard (MA), AT&T (T) and Twilio (TWLO).

Who are Hill-Rom's key executives?

Hill-Rom's management team includes the folowing people:

Mr. John P. Groetelaars, Pres, CEO & Director (Age 52)
Mr. Carlos Alonso-Marum, Sr. VP & Pres of International (Age 60)
Mr. Paul Johnson, Sr. VP & Pres of Patient Support Systems (Age 54)
Mr. Steven J. Strobel, Sr. Advisor (Age 61)
Ms. Barbara W. Bodem, Sr. VP & CFO (Age 51)

Who are Hill-Rom's major shareholders?

Hill-Rom's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boston Trust Walden Corp (0.44%), Johanson Financial Advisors Inc. (0.38%), Mountain Pacific Investment Advisers Inc. ID (0.32%), Wedge Capital Management L L P NC (0.20%), CHURCHILL MANAGEMENT Corp (0.08%) and Three Peaks Capital Management LLC (0.07%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.

Which institutional investors are selling Hill-Rom stock?

HRC stock was sold by a variety of institutional investors in the last quarter, including Three Peaks Capital Management LLC, Gateway Investment Advisers LLC, Sciencast Management LP, Nisa Investment Advisors LLC, Campbell & CO Investment Adviser LLC, CHURCHILL MANAGEMENT Corp, State of Alaska Department of Revenue and Huntington National Bank. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.

Which institutional investors are buying Hill-Rom stock?

HRC stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Boston Trust Walden Corp, Mountain Pacific Investment Advisers Inc. ID, Assenagon Asset Management S.A., AE Wealth Management LLC, Strategic Investment Advisors MI, First Hawaiian Bank and Wedge Capital Management L L P NC. View Insider Buying and Selling for Hill-Rom.

How do I buy shares of Hill-Rom?

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hill-Rom's stock price today?

One share of HRC stock can currently be purchased for approximately $113.62.

How big of a company is Hill-Rom?

Hill-Rom has a market capitalization of $7.61 billion and generates $2.91 billion in revenue each year. The medical technology company earns $152.20 million in net income (profit) each year or $5.08 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.View Additional Information About Hill-Rom.

What is Hill-Rom's official website?

The official website for Hill-Rom is http://www.hill-rom.com/.

How can I contact Hill-Rom?

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]

MarketBeat Community Rating for Hill-Rom (NYSE HRC)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		356 (Vote Outperform)
Underperform Votes:		373 (Vote Underperform)
Total Votes:		729

MarketBeat's community ratings are surveys of what our community members think about Hill-Rom and other stocks. Vote "Outperform" if you believe HRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRC will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/23/2020 by MarketBeat.com Staff